Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 4Thoracic 1Other solid neoplasm 1NET 1Gynecologic 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 394Carcinoid Tumor 49Gastro-enteropancreatic neuroendocrine tumor 42Neoplasms 36Carcinoma, Neuroendocrine 36Adenoma, Islet Cell 27Neoplasm Metastasis 23Pancreatic Neoplasms 22Colorectal Neoplasms 21Pheochromocytoma 20Paraganglioma 19Sarcoma 15Gastrointestinal Neoplasms 15Carcinoma 14Breast Neoplasms 14Stomach Neoplasms 13Prostatic Neoplasms 13Neuroblastoma 13Lung Neoplasms 13Carcinoma, Hepatocellular 13Thyroid Neoplasms 12Small Cell Lung Carcinoma 12Carcinoma, Renal Cell 11Cholangiocarcinoma 10Neuroectodermal Tumors, Primitive 9Carcinoma, Non-Small-Cell Lung 9Somatostatinoma 8Serotonin Syndrome 8Digestive System Neoplasms 8Brain Neoplasms 8

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Parotid Neoplasms × NET × Clear all
NCT02628067 2025-09-22

KEYNOTE 158

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
1,609 enrolled 4 FDA
EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡